David Linetsky - Nov 5, 2021 Form 4 Insider Report for Phreesia, Inc. (PHR)

Role
SVP, Life Sciences
Signature
/s/ Allison Hoffman by Power of Attorney for David Linetsky
Stock symbol
PHR
Transactions as of
Nov 5, 2021
Transactions value $
-$350,548
Form type
4
Date filed
11/9/2021, 03:50 PM
Previous filing
Nov 2, 2021
Next filing
Jan 7, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHR Common Stock Options Exercise $16.4K +3.48K +2.48% $4.71* 144K Nov 5, 2021 Direct F1, F2
transaction PHR Common Stock Sale -$261K -3.48K -2.42% $75.15 140K Nov 5, 2021 Direct F1, F2, F3
transaction PHR Common Stock Options Exercise $7.06K +1.5K +1.07% $4.71* 142K Nov 8, 2021 Direct F1, F2
transaction PHR Common Stock Sale -$113K -1.5K -1.06% $75.12 140K Nov 8, 2021 Direct F1, F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PHR Stock Option Options Exercise $0 -3.48K -54.34% $0.00 2.92K Nov 5, 2021 Common Stock 3.48K $4.71 Direct F1, F5
transaction PHR Stock Option Options Exercise $0 -1.5K -51.3% $0.00 1.42K Nov 8, 2021 Common Stock 1.5K $4.71 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.32 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 25% of this option shall vest and become exercisable on January 31, 2019, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.